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Neurons are metabolically active cells with high energy demands at locations distant from the cell body. As a
result, these cells are particularly dependent on mitochondrial function, as reflected by the observation that
diseases of mitochondrial dysfunction often have a neurodegenerative component. Recent discoveries have
highlighted that neurons are reliant particularly on the dynamic properties of mitochondria. Mitochondria are
dynamic organelles by several criteria. They engage in repeated cycles of fusion and fission, which serve to
intermix the lipids and contents of a population of mitochondria. In addition, mitochondria are actively
recruited to subcellular sites, such as the axonal and dendritic processes of neurons. Finally, the quality
of a mitochondrial population is maintained through mitophagy, a form of autophagy in which defective mito-
chondria are selectively degraded. We review the general features of mitochondrial dynamics, incorporating
recent findings on mitochondrial fusion, fission, transport and mitophagy. Defects in these key features are
associated with neurodegenerative disease. Charcot-Marie-Tooth type 2A, a peripheral neuropathy, and
dominant optic atrophy, an inherited optic neuropathy, result from a primary deficiency of mitochondrial
fusion. Moreover, several major neurodegenerative diseases—including Parkinson’s, Alzheimer’s and
Huntington’s disease—involve disruption of mitochondrial dynamics. Remarkably, in several disease
models, the manipulation of mitochondrial fusion or fission can partially rescue disease phenotypes. We
review how mitochondrial dynamics is altered in these neurodegenerative diseases and discuss the recipro-
cal interactions between mitochondrial fusion, fission, transport and mitophagy.
INTRODUCTION
In the past decade, our view of mitochondrial dynamics has
expanded from a curious phenomenon into an integral cell bio-
logical process influencing many cellular functions and ulti-
mately survival (1,2). Once thought to be solitary and rigidly
structured, mitochondria are now appreciated to constitute a
population of organelles that migrate throughout the cell, fuse
and divide, and undergo regulated turnover. These dynamic
processes regulate mitochondrial function by enabling mito-
chondrial recruitment to critical subcellular compartments,
content exchange between mitochondria, mitochondrial shape
control, mitochondrial communication with the cytosol and
mitochondrial quality control. As a result, mitochondria can
readily adapt to changes in cellular requirements, whether
due to physiological or environmental imperatives. When mito-
chondrial dynamics is disrupted, cellular dysfunction ensues.
Here we discuss the human diseases associated with abnormal-
ities in mitochondrial dynamics.
DISEASES OF MITOCHONDRIAL FUSION:
CONVERGING PHENOTYPES
Three mammalian proteins are required for mitochondrial
fusion (1): Mfn1 and Mfn2 for outer membrane fusion, and
OPA1 for inner membrane fusion (3,4). Mouse knockouts of
each of these three genes result in embryonic lethality and
mitochondrial dysfunction (5–7). Mutations in Mfn2 cause
Charcot-Marie-Tooth type 2A (CMT2A), a peripheral
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neuropathy affecting sensory and motor neurons of the distal
extremities (8). Mutations in OPA1 are the predominant
cause of autosomal dominant optic atrophy (DOA), a degener-
ation of retinal ganglia cells that leads to optic nerve atrophy
(9,10). A frequently asked question is why mutations in two
proteins both required for mitochondrial fusion should cause
two diseases with such different tissue specificity. Potential
answers include differential expression patterns between
Mfn2 versus OPA1, functional differences between OPA1
(11) and Mfn2 (12), differences in an outer membrane
fusion defect versus an inner membrane fusion defect (4)
and redundancy between Mfn1 and Mfn2 (6,13).
Although all of these explanations may apply, more overlap
in the clinical manifestations of CMT2A and DOA has
emerged with the study of additional affected families. In
addition to optic atrophy, some DOA patients present with
additional symptoms, including peripheral motor-sensory neu-
ropathy. Sensorineural deafness, cerebral atrophy, cerebellar
ataxia, chronic progressive external ophthalmoplegia, mito-
chondrial myopathy and psychiatric involvement can also
manifest (14,15). Similarly, some CMT patients with Mfn2
mutations suffer from optic atrophy as well as deafness, cog-
nitive dysfunction, cerebral and cerebellar abnormalities,
vocal cord paresis, scoliosis, parkinsonism and psychiatric
involvement (16–21). In addition, the same mutation (e.g.
R94W) can generate a large range of phenotypes even
within the same family. Therefore, modifying factors clearly
play a role in determining manifestation of the diseases. In
fact, one patient with an OPA1 mutation notably does not
have optic atrophy, but instead displays ptosis, hearing loss,
proximal weakness, psychiatric involvement and muscle mito-
chondrial dysfunction (22).
In summary, mutations in either OPA1 orMfn2 can impact a
broad range of tissues beyond the optic and peripheral nerves.
The overlapping symptoms in DOA and CMT2A families
suggest that OPA1 and Mfn2 mutations can affect certain
tissues in a similar way. Interestingly, the widespread CNS
involvement and myopathies are reminiscent of mtDNA
mutation syndromes. Indeed, OPA1 ‘plus’ patients actually
harbor mitochondrial DNA (mtDNA) deletions in their
muscle cells, suggesting a role for mitochondrial fusion in
maintaining mtDNA integrity (14,15).
IMPACT OF MITOCHONDRIAL FISSION ON
FUNCTION
As in yeast (Dnm1), flies (Drp1) and plants (DRP3B), mito-
chondrial fission in mammals is mediated by a dynamin-like
protein, Drp1 (1). Drp1 is a predominantly cytosolic protein
that is recruited to mitochondria during fission. In yeast, this
recruitment is clearly dependent on the mitochondrial outer
membrane protein Fis1 (2). In mammalian cells, however,
knockdown of Fis1 blocks mitochondrial fission without
affecting Drp1 localization to mitochondria (23). Recent
studies have identified another tail-anchored outer membrane
protein, Mff, which is involved in mitochondrial fission.
Knockdown of Mff causes mitochondrial elongation and
resistance to CCCP-induced fragmentation (24). Blue native
gel studies show that Fis1 and Mff reside in complexes of
different sizes, suggesting distinct machineries for mitochon-
drial fission. The potential role of Mff in Drp1 recruitment
to mitochondria remains to be tested.
Although no inherited diseases are known to result from
mutation of these genes, one case of neonatal lethality has
been attributed to a defect in Drp1 (25). This patient carried
a dominant-negative allele that caused perinuclear tangles of
elongated, large-diameter mitochondria. Symptoms included
optic atrophy, a notably small head with abnormal brain devel-
opment and hypoplasia. Lactic acid levels were elevated in the
blood and even more so in the cerebral spinal fluid (CSF).
Muscle and fibroblasts showed normal respiratory function,
but it seems likely that neuronal cells had electron transport
chain (ETC) abnormalities, given the extreme lactic acid con-
centrations in the CSF and the brain structural defects. In cell
culture studies, down-regulation of Drp1 in HeLa cells causes
slower cell growth, loss of mtDNA, uncoupling of the ETC,
decreased cellular respiration and increased reactive oxygen
species levels (26).
Therefore, like mitochondrial fusion, fission seems to be
required to maintain mitochondrial function. The mechanisms,
however, probably differ. Fusion is likely to protect function
by providing a chance for mitochondria to mix their contents,
thus enabling protein complementation, mtDNA repair and
equal distribution of metabolites. Fission likely acts instead
to facilitate equal segregation of mitochondria into daughter
cells during cell division and to enhance distribution of mito-
chondria along cytoskeletal tracks. In addition, fission may
help to isolate damaged segments of mitochondria and thus
promote their autophagy as discussed below (27). When
these protective mechanisms fail, mitochondrial fission can
also promote apoptosis, an important topic that has been
extensively reviewed (28).
EMERGING ASPECTS OF MITOCHONDRIAL
DYNAMICS
Perturbations in mitochondrial fusion, fission, motility and
turnover can lead to distinctive defects in neurons (Fig. 1).
However, there is also substantial overlap in these defects,
because these four processes are interdependent. The recipro-
cal interactions between these processes are becoming
appreciated, but our molecular understanding is still sparse.
Mitophagy
Autophagy is a process whereby cellular components are
degraded by engulfment into autophagosomes. Autophago-
somes fuse with lysosomes, which contain hydrolytic
enzymes that break down cellular components. During nutrient
deprivation, the products can be recycled into more urgently
needed molecules. Although autophagy plays a particularly
prominent role during starvation, it also appears to have a
housekeeping role in maintaining quality control by turning
over organelles and degrading protein aggregates. Mitophagy
denotes the degradation of mitochondria through autophagy.
Although the existence of mitophagy has been known for
some time, it has been unclear whether mitochondria are
randomly or selectively targeted for mitophagy.
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Several recent findings indicate that mitophagy can selec-
tively degrade defective mitochondria. In yeast cells, mito-
phagy is regulated independently from bulk autophagy (29).
Mitochondria that are damaged by a laser irradiation in hep-
atocytes are selectively removed by mitophagy (30). Studies
in pancreatic b-cells and COS7 cells show that mitochondrial
fission can yield uneven products, with one depolarized daugh-
ter mitochondrion and one hyperpolarized mitochondrion (27).
Such depolarized mitochondria are much less likely to fuse,
have reduced levels of OPA1 protein, and are eventually
autophagocytosed. This mitophagy is dependent on loss of
fusion and the presence of fission, because OPA1-
overexpression, Fis1 RNAi, and Drp1 dominant-negative
expression all reduce levels of mitophagy. When mitophagy
is thus compromised, oxidized proteins accumulate, and cellu-
lar respiration and insulin secretion decrease. It is important to
note that although mitochondrial fragmentation is permissive
for mitophagy, it is not a sufficient signal for mitophagy
(27,31).
Mitochondrial motility
Another aspect of mitochondrial dynamics beyond fusion and
fission is the motility of mitochondria. This aspect is critically
important in highly polarized cells, such as neurons (32),
which require mitochondria at sites distant from the cell
body, but can also be crucial to cellular function in smaller
cells (33). Defects in both fusion and fission have been
shown to decrease mitochondrial movement. Presumably,
the large tangle of highly interconnected mitochondria in
fission-deficient cells prevents efficient movement, especially
into small pathways such as neuronal processes (34,35). In
fusion-deficient cells, the cause of decreased motility is less
clear. Empirically, however, fusion-deficient mitochondria
display loss of directed movement, instead hovering in a
manner reminiscent of Brownian motion (6). In neurons
lacking mitochondrial fusion, both increased mitochondrial
diameter due to swelling and aggregations of mitochondria
seem to block efficient entry into neurites, resulting in a
dearth of mitochondria in axons and dendrites (36). These
defects result in improperly developed neurons or gradual
neurodegeneration.
Mitochondrial transport in mammalian cells is largely
microtubule based (32). Anterograde motion is driven by the
kinesin-1 motor (KHC, Kif5b), which interacts with mitochon-
dria through the outer membrane proteins Miro1 and Miro2
(37). In Drosophila, Milton is an adapter protein that mediates
binding of Miro to kinesin. High local concentrations of
calcium act through the EF hands of Miro to halt mitochon-
drial movement, and thus retain mitochondria at sites where
ATP production and Caþþ buffering are needed (38–40).
Loss of this Miro-dependent transport pathway in neurons
results in depletion of mitochondria from dendrites and
axons, resulting in neurotransmission defects during prolonged
stimulation (41).
How this mitochondrial transport apparatus interacts with
the fusion/fission machinery is unclear, but most likely
involves indirect interactions. Deletion of Miro in yeast
greatly affects mitochondrial morphology without disrupting
mitochondrial fusion or fission (42). Likewise in mammalian
cells, manipulation of Miro can dramatically affect mitochon-
drial shape (39,43,44). Disruption of dynein function, which is
Figure 1. Defects in mitochondrial dynamics that lead to neuronal dysfunction. (A) In wild-type neurons, mitochondria travel long distances from the cell body
out to dendritic and axonal termini, where they play important roles in ATP production and calcium homeostasis. (B) In the absence of fusion, the mitochondrial
population fragments and a subset show ultrastructural defects and dysfunction (red). The mitochondria secondarily have transport defects that prevent proper
distribution to the periphery. (C) In the absence of fission, the mitochondrial population is excessively long and interconnected, and a subset shows dysfunction
(red). These large mitochondria cluster within the cell body and are not efficiently transported to the periphery. (D) Primary defects in mitochondrial motility
prevent distribution of mitochondria to the periphery. (E) In the absence of mitophagy, abnormal mitochondria (red) accumulate.
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necessary for retrograde transport of mitochondria, sequesters
Drp1 in the cytoplasm and results in perinuclear, elongated
mitochondria (45). Therefore, mitochondrial fusion and fission
defects secondarily impair motility, and conversely, transport
defects affect mitochondrial morphology. However, the mecha-
nisms underlying this interplay remain to be determined.
NEURODEGENERATIVE DISEASES INVOLVING
MITOCHONDRIAL DYNAMICS
Aside from diseases such as DOA and CMT2A caused by per-
turbation of mitochondrial fusion, mitochondrial dynamics
seems to impact a wide variety of human diseases through
interactions with other cellular processes. Many of these dis-
eases are neurodegenerative and affect many distinct regions
of the brain as well as the peripheral nervous system
(Fig. 2), again emphasizing the importance of mitochondrial
function in maintaining healthy neurons.
Parkinson’s disease
Progressive loss of dopaminergic neurons in the substantia
nigra leads to Parkinson’s disease (PD), the second most
common neurodegenerative disease in humans. The most
prominent PD symptoms include a resting tremor, rigidity,
bradykinesia and a characteristic unsteady gait. Both chemical
and genetic lines of evidence strongly suggest mitochondrial
involvement. Drugs that inhibit complex I of the ETC
produce PD-like symptoms in humans and animal models.
The majority of PD cases are sporadic with unclear etiology.
However, 10% of PD cases are inherited, and linkage analy-
sis has identified a number of PD-associated genes. Two genes
identified in hereditary PD are Pink1 and Parkin, both of
which have been shown to be important for mitochondrial
integrity (46). Pink1 is a serine/threonine kinase with an
N-terminal mitochondrial targeting sequence and is localized
to both mitochondria and the cytosol. Parkin is a cytosolic
E3 ubiquitin ligase with two RING fingers, cysteine- and
histidine-containing protein motifs that coordinate zinc ions.
Studies of mammalian Pink1 and Parkin have been compli-
cated by the fact that mouse knockouts have little phenotype
and fail to reproduce the common symptoms of PD (47–49).
However, mitochondria from both knockouts demonstrate
mild defects in respiration and sensitivity to oxidative stress
(47,49–51). Additional studies show that loss of Pink1 can
result in abnormalities in mitochondrial morphology, but the
effects differ among cell types. Loss of Pink1 in human dopa-
minergic neurons or primary mouse neuronal cultures leads to
reduced viability accompanied by abnormal, swollen mito-
chondria (52). Mitochondria from Pink12/2 mouse striatal
neurons show no gross ultrastructural changes, although a
small increase in the number of large mitochondria is observed
(50). Knockdown of Pink1 in COS7 cells also increases
Figure 2. Neurodegenerative disease associated with defects in mitochondrial dynamics. Neuronal systems affected in neurodegenerative disease are shown. For
each disease, only the primary affected regions are indicated, but there is evidence for more widespread involvement.
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mitochondrial size through tubulation. This effect is sup-
pressed by hFis1 or Drp1 over-expression (53). In contrast,
PD patient fibroblasts were reported to contain fragmented
mitochondria (54). Similarly, knockdown of Pink1 in HeLa
cells and human neuronal SH-SY5Y cells causes mitochon-
drial fragmentation, an effect reversed by over-expression of
Parkin (54,55).
Whereas mouse knockouts of Pink1 or Parkin have subtle
phenotypes, the corresponding mutants in flies show severe
mitochondrial dysfunction in multiple tissues (56–59). Both
mutants are remarkably similar, marked by flight muscle
degeneration accompanied by swollen mitochondria with dis-
rupted cristae. Double mutants have a similar phenotype.
Parkin over-expression restores muscle integrity and flight to
pink1 mutants, but Pink1 over-expression in parkin mutants
has no effect. These findings have led to the model that
Pink1 and Parkin likely act in the same pathway, with
Parkin downstream of Pink1 (56,58,59). Consistent with this
model, there is biochemical evidence for a direct interaction
between Pink1 and Parkin (60).
How does the Pink1/Parkin pathway regulate mitochondrial
function? Recent genetic studies in flies suggest that Pink1 and
Parkin act to promote mitochondrial fission or inhibit fusion
(53,61,62). Over-expression of Drp1 or down-regulation of
Marf/Mfn2 (a fly homologue of mammalian Mfns) or Opa1
can dramatically ameliorate the phenotypes of pink1 or
parkin mutant flies, including flight muscle degeneration,
abnormal wing posture and defects in climbing and flying.
These striking observations indicate a genetic interaction
between the Pink1/Parkin pathway and mitochondrial
dynamics. However, some observations suggest that the
relationship may not be direct. For example, the epistatic
relationship of Pink1/Parkin to mitochondrial fusion and
fission is not straightforward. With regard to mitochondrial
morphology in muscle, drp1, marf and opa1 mutations are
epistatic to pink1 and parkin mutations. In the testicular
mitochondria, however, a pink1 mutation is epistatic to
an fzo mutation (61). Furthermore, although pink1 or parkin
mutants have some enlargement of mitochondria, this morpho-
logical change is accompanied by increased apoptosis and is
different from that of drp1 mutants. In addition, a synthetic
lethal interaction is seen in pink1-null, drp1-heterozygous
flies. These data indicate that Pink1/Parkin do not act in a
simple linear pathway with either mitochondrial fission or
fusion.
In the studies of PD, interpretation of the functions of Pink1
and Parkin have been complicated by the discrepancies in
mitochondrial morphology defects found among various mam-
malian cell lines and between the fly and mammalian model
systems. Such complexity is also apparent in studies of
Alzheimer’s disease (AD) and Huntington’s disease (HD)
(later). In part, these discrepancies may suggest that Pink1
and Parkin do not directly regulate mitochondrial fusion or
fission in a straightforward manner. Mitochondrial mor-
phology is highly dependent on mitochondrial physiology,
and therefore it can be difficult to interpret changes in mito-
chondrial shape. In particular, the cause of mitochondrial frag-
mentation can be indirect, because it frequently accompanies
mitochondrial dysfunction. In Caenorhabditis elegans, an
RNAi screen revealed that disruption of over 80% of
mitochondrial genes leads to mitochondrial fragmentation
and/or aggregation, showing that this morphological phenotype
is an extremely common one and not necessarily an indication
of a specific effect on mitochondrial fusion or fission (63).
Recent studies implicate Parkin in the turnover of mitochon-
dria through mitophagy. Parkin is specifically recruited to
mitochondria with low membrane potential, and these targeted
mitochondria are then destroyed through the autophagosome
(31). The mitochondrial accumulation of Parkin is voltage-
dependent, and does not depend on changes in pH or ATP
levels (64). These experiments suggest that Parkin may act
as a sensor for mitochondrial integrity and trigger mitophagy
upon dysfunction. It is unclear whether Pink1 is involved in
this pathway. Knockdown of Pink1 in SH-SyY5Y cells
induces mitochondrial fragmentation, accumulation of
mitochondrially-targeted autophagosomes and increased cell
death (55). Inhibition of Drp1 prevents mitochondrial frag-
mentation and mitophagy, but exacerbates cell death.
Co-expression of Parkin, though, increases mitophagy and
decreases cell death while at the same time preventing mitochon-
drial fragmentation. In this case, mitochondrial morphology
itself does not appear to be the critical component in determining
cell fate. Rather, the functional state of the mitochondrial popu-
lation appears to govern the cellular outcome. Taken together,
these results suggest that Pink1 protects mitochondrial function,
whereas Parkin promotes mitochondrial quality control by elim-
inating dysfunctional mitochondria. In future studies, it will be
important to test whether Parkin-deficient cells from PD patients
indeed have a defect in mitophagy.
Alzheimer’s disease
The most common neurodegenerative disease, AD, is marked
by cognitive dysfunction and memory loss caused by neuronal
death in the cerebral cortex. Afflicted brains carry intracellular
neurofibrillary tangles and extracellular amyloid plaques com-
posed chiefly of beta-amyloid (Ab) derived from amyloid pre-
cursor protein (APP). Although the pathological mechanism
for AD is still unknown, the predominant hypothesis is that
excess Ab production results in cellular toxicity. Transgenic
mouse models over-expressing APP lead to amyloid plaques
associated with activation of inflammatory cells, localized
loss of neurons, and some cognitive behavioral changes (65).
Abnormalities in mitochondrial structure are found in the
brain of AD patients (66). Ab can localize to mitochondria,
and this interaction has been suggested to underlie in part
their cytotoxic effects (67,68). Exposure of neuronal cells
to conditioned medium from cells stably expressing mutant
forms of APP leads to increased mitochondrial fission, loss
of dendritic spines and eventually cell death (69). This
increase in mitochondrial fission was traced to elevated
levels of S-nitrosylated Drp1 (SNO-Drp1), which is suggested
to have increase fission activity due to enhanced dimerization.
Expression of Drp1(C644A), a mutant incapable of nitrosyla-
tion, prevents excessive mitochondrial fission and neuronal
cell injury without interfering with normal, basal levels
of mitochondrial fission. Moreover, increased levels of
SNO-Drp1 were found in brain samples from AD patients
and AD mouse models. These data suggest that the cytotoxic
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effects of Ab result, in part, from generation of nitric oxide
that leads to activation of Drp1 activity.
In contrast, another study found that fibroblasts from spora-
dic AD patients express lower levels of Drp1 and display
elongated mitochondria which form collapsed perinuclear net-
works (70,71). The same group, however, found that APP
over-expression in M17 neuroblastoma cells resulted in predo-
minantly fragmented mitochondria, decreased levels of Drp1
and OPA1, and a defect in neuronal differentiation (72). Over-
expression of Drp1 or OPA1 could partially rescue different
aspects of these defects.
Huntington’s disease
Progressive loss of striatal and cortical neurons leads to cognitive
and motor impairment and eventually death in patients with HD.
Whereas multiple genes have been associated with PD and AD,
HD is an autosomal dominant disease caused by trinucleotide
expansion [cytosine, adenine, and guanine (CAG)] within a
single gene, huntingtin (Htt). Disease is associated with CAG
expansion leading to a stretch of glutamines beyond 35 residues
in Htt. In HD patients and mouse transgenic HD models, several
lines of evidence indicate that expression of mutant Htt is associ-
ated with mitochondrial dysfunction (73). For example, Htt
expression correlated with elevated lactate levels, decreased
mitochondrial membrane potential, decreased respiratory func-
tion through complex II, defects in mitochondrial calcium
uptake, reduced mitochondrial mobility and mitochondrial ultra-
structural changes. In animal models, 3-nitropropionic acid, an
irreversible inhibitor of complex II, can cause HD-like symp-
toms. Conversely, over-expression of complex II subunits can
prevent cell death in striatal neurons carrying mutant Htt.
Recent studies uncover an interplay between HD and
mitochondrial dynamics. Rat cortical neurons treated with
3-nitropropionic acid have fragmentation and condensation
of mitochondria which can be prevented by antioxidant treat-
ment (74). Likewise, mitochondria in HeLa cells over-
expressing a mutant Htt with a 74 glutamine repeat (Htt74Q)
show fragmentation of mitochondria, reduced mitochondrial
fusion, reduced ATP and increased cell death (75). Remark-
ably, expression of either dominant-negative Drp1 or Mfn2
not only prevents this change in mitochondrial morphology,
but also restores ATP levels and attenuates cell death. Inhi-
bition of Drp1 can also rescue the mobility of worms expres-
sing Htt74 in muscle cells.
Because increasing fusion or reducing fission can partially
rescue mutant Htt over-expression, it is possible that mutant
Htt disrupts fusion and fission. However, it is unclear
whether such a direct relationship exists. Mutant Htt can
associate with mitochondria (76), but the biochemical function
of Htt remains poorly understood. It is possible that, in some
cellular environments, manipulation of fusion and fission
rates can improve the physiology of mitochondria even if
the initial insult is not directly on fusion or fission. Mutant
Htt expression has multiple effects on mitochondrial physi-
ology, including respiratory dysfunction and reduced trans-
port. Htt72Q transgenic mice display a generalized transport
defect in neurons (77), including abnormal movement of
mitochondria (76–78). The mitochondria move more slowly,
stop more frequently and travel shorter distances. Defects in
membrane potential, respiratory distress and inefficient trans-
port can all secondarily contribute to the morphological
defects associated with mutant Htt expression.
PERSPECTIVE
Taken together, the studies reviewed here clearly indicate that
perturbations in mitochondrial dynamics are directly or
indirectly involved in a host of human neurodegenerative dis-
eases. However, our understanding of the mechanisms
involved remains rudimentary at best. There exists much con-
flicting data among different disease models, especially
regarding the mitochondrial morphological changes associated
with disease states and the mechanisms underlying these
changes. Several factors likely contribute to these discrepan-
cies. First, the variations in mitochondrial phenotypes
suggest that although PD, AD and HD clearly perturb mito-
chondrial dynamics, the effects are unlikely to result from
simple, direct effects on the processes of fusion and fission.
Second, it is becoming increasingly clear that a myriad of
factors can affect mitochondrial shape. For each disease, it
will be important to dissect the key underlying mechanisms.
As we learn more about how neurodegenerative diseases
impact mitochondria, it is becoming clear that mitochondrial
dynamics is a multi-factorial process that is integrated into
cell physiology. Mitochondrial fusion and fission play promi-
nent roles in controlling mitochondrial shape and function.
However, these opposing processes have reciprocal inter-
actions with mitochondrial transport and mitophagy. There-
fore, several inter-related factors—fusion, fission, transport
and turnover—form a complex interacting network that
governs mitochondrial function and thereby cellular integrity.
A challenge for future studies is to unravel the molecular
nature of these interactions. Given that manipulation of
genes controlling mitochondrial fusion and fission can amelio-
rate disease phenotypes, there is compelling reason to hope
that efforts to artificially manipulate mitochondrial dynamics
(79) will ultimately lead to new therapeutic approaches.
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NOTE ADDED IN PROOF
Mihara (80) and colleagues have recently disrupted Drp1 in
mice and have provided additional evidence for the role of
mitochondrial fission in neuronal development. Embryonic
neurons lacking Drp1 show improper mitochondrial distri-
bution consistent with Figure 1 and increased sensitivity to
apoptosis.
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